American Society of Hirudotherapy

Comparison of two pediatric cases requiring the use of bivalirudin during cardiopulmonary bypass

Bryant ME, Regan WL, Fynn-Thompson F, Hoganson D, Nasr VG, Zaleski K, Faella K, Matte GS (2018) · Perfusion · n=2

Observational study: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
GRADE Very LowCohort / case seriesBivalirudin: drug studies

Study Profile

Design
case comparison of two pediatric cardiopulmonary bypass cases (bilateral lung transplant and ventricular assist device implantation) using identical bivalirudin protocol
Sample size (n)
2
Intervention
Bivalirudin 1 mg/kg bolus + 50 mg pump prime + 2.5 mg/kg/h infusion titrated to K-ACT >400s during CPB
Main result
BLT case maintained K-ACT >720s despite reducing infusion to 0.5 mg/kg/h; VAD case required infusion increase to 5.0 mg/kg/h for low K-ACTs; both cases successful but highlight dose variability
Follow-up duration
CPB run duration

Key Findings

  • 10-fold variability in bivalirudin dose requirements between two pediatric CPB cases
  • BLT case over-anticoagulated, VAD case required dose escalation
  • Same starting protocol but dramatically different titration needed
  • Recommends minimum infusion of 0.5 mg/kg/h
  • One-page timeline protocol shared for adoption

Limitations

  • Only 2 cases - case comparison not generalizable
  • Single-center experience
  • Heterogeneous clinical scenarios (transplant vs VAD)
  • K-ACT not validated against direct bivalirudin levels
  • Not applicable to whole-leech hirudotherapy

Clinical Implications

Bryant 2018 documents extreme inter-patient dose variability in pediatric CPB bivalirudin use, motivating individualized monitoring protocols. For ASH, this Boston Children's case comparison illustrates how the synthetic thrombin inhibitor pharmaceutical pathway requires substantial institutional protocolization, distinct from the K040187 device-leech US clinical practice where dose-equivalent considerations are clinically simpler (number and duration of leech sessions).

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.